CN105963687A - Compound preparation for treating chronic pelvic pain and preparation method of compound preparation - Google Patents
Compound preparation for treating chronic pelvic pain and preparation method of compound preparation Download PDFInfo
- Publication number
- CN105963687A CN105963687A CN201610273805.2A CN201610273805A CN105963687A CN 105963687 A CN105963687 A CN 105963687A CN 201610273805 A CN201610273805 A CN 201610273805A CN 105963687 A CN105963687 A CN 105963687A
- Authority
- CN
- China
- Prior art keywords
- parts
- compound preparation
- pelvic pain
- chronic pelvic
- treating chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a compound preparation for treating chronic pelvic pain and a preparation method of the compound preparation. The compound preparation consists of the following components: medroxyprogesterone acetate, serotonin, wulin powder, eleutheroside, oryzanol, volatile oil of bock greenbrier rhizome, adrenocortical hormone, estradiol valerate, dydrogesterone, betulonic acid of beautiful sweetgum fruit, lactoferrin, soybean lecithin and xylaria ketone. The compound preparation disclosed by the invention has functions of resisting inflammation, taking an immunosuppressive action effect, tranquilizing and relieving pain; moreover, the compound preparation has an effect on regulating patient's emotion, and is capable of effectively preventing diseases from getting worsened due to the emotion; meanwhile, the compound preparation can regulate ovarian functions and relieve pelvic congestion and pelvic pain; and upon clinical verification, the compound preparation is significant in curative effect on treating the chronic pelvic pain and is broad in application prospect.
Description
Technical field
The present invention relates to Amino-Cerv technical field, be specifically related to a kind of compound recipe for treating chronic pelvic pain
Preparation and preparation method thereof.
Background technology
Chronic pelvic pain (CPP) is a kind of common complicated symptom making people weak, and its cause of disease is the most unclear.It
Relevant to the most ill and forfeiture health and sexual function.The symptom of patient's Chang Yinqi sustainable development, weigh on a large scale
Reinspection look into and existing medical science can not efficient diagnosis and treatment and agonize.Many patients also illustrate that, because of can not
Allow other people take seriously its pain, or be prompted its pain and may cause because of psychological causes, and feel the most dejected.
Chronic pelvic inflammation is to cause the modal reason of pelvic pain.Most of chronic inflammatory diseases have acute inflammation
History.The most heavier because infecting, body constitution is more weak, and treatment not in time or does not thoroughly delay and becomes chronic.Often betide
In puerperal, miscarriage or artificial abortion, the infection after unclean sexual life etc., then by uterus, the office of endosalpinx
Portion's inflammation diffusion, causes surrounding connective tissue or pelvic peritoneum to be inflamed through muscle layer.After acute stage, because of basin
Chamber drain not poplar, lacuna is more, makes inflammatory exudate pool amass slime flux, stretches to surrounding tissue, forms adhesion,
Wrapped folder chronic lesion, standby recurrence；Or pass to adjacent organs and form swollen leakage.Sometimes small opening is minimum, time when closing
Open, cause the prolonged and repeated outbreak of inflammation, form cicatrix, some formation microabscesses and ulcer, prolonged do not heal.Scar
Trace adhesion often causes organ displacement, such as retroflextion, fixes, and descensus ovarii increases the weight of again pelvic pain.Due to blood
Circulatory disturbance, congestion in basin, stimulate pelvic nerve and prolonged and repeated generation in various degree with the pelvic pain of character.
Additionally, the cervical edema caused by acute and chronic cervicitis, loose, severe is rotten to the corn, cervical ectropion and multiple pool
The property stayed cyst, is also that compressing stimulates male pelvic plexus, causes lower abdomen pendant pain and the common cause of leukorrhagia.
Unknown cause or non-organic pelvic pain are implicitly present in.I.e. relevant with mental status.It is more common in sensitivity
Type women, introverted or impetuous person.By certain spiritual influence, genital organ disease is had potential misgivings；Basin
Intracavity has recessive ligament or fascia or this wound of muscle or fracture.On a rare occasion touch or involved and (such as firmly defecation, cough
Cough, when the abdominal pressure such as vomiting and nausea increases) severe pain in sense pelvic cavity；Phantom pain.Pelvic cavity genitals's excision, plan
Give birth to postoperative, pain in pelvic cavity often occurs because of thought misgivings.
Summary of the invention
The technical problem to be solved in the present invention be to provide a kind of compound preparation for treating chronic pelvic pain and
Its preparation method.
The technical scheme is that a kind of compound preparation for treating chronic pelvic pain, including following heavy
The composition of amount part: medroxyprogestetone acetate 17～26 parts, serotonin 15～23 parts, powdered Wuling mycelia in combination 13～21 parts, thorn
Acanthoside 10～19 parts, oryzanol 26～34 parts, lactoferrin 12～25 parts, preservative 0.8～1.2 parts, breast
Agent 6～9 parts, PH regulator 8～14 parts.
Further, the composition of following weight portion is also included: dydrogesterone 3～8 parts, Fructus Liquidambaris betulonic acid
9～14 parts, Xylaria sp. fungus ketone 7～15 parts, estradiol valerate 5～11 parts.
Further, the composition of following weight portion is also included: Rhizoma Smilacis Bockii volatile oil 21～29 parts, soybean lecithin
9～16 parts, adrenocortical hormone 8～13 parts.
Further, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN silk by submerged fermentation technology
Body, and it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN is inoculated into containing water, carbonizable substance,
On the fluid medium of nitrogen material, mineral element and auxin substance composition, sealing, shaking at 20～30 DEG C
Swinging cultivation 10～12 days, media surface there will be one layer of mycelium, is then divided by the mycelium on culture medium top layer
From, it is dried.Smash and i.e. obtain described powdered Wuling mycelia in combination.
Further, described preservative is: methyl hydroxybenzoate.For organic intermediate, for medicine, food,
Spice, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By to hydroxyl
Benzoic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent be: any one in lecithin, poloxamer, arabic gum, tween and span.Emulsifying agent
Mainly promote the dispersion of mutual exclusive system, form homogeneous system；Described PH regulator is: di(2-ethylhexyl)phosphate
One in hydrogen sodium, disodium hydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from changing
Affect drug effect.
Further, described Xylaria sp. fungus ketone is to be extracted from big Xylaria sp. fungus by ultrasonic wave added with ethanol for solvent
's.Xylaria sp. fungus ketone has adjustment effect, can improve immunologic function, strengthen hematopoietic function, to such as anemia,
Insomnia, menoxenia, female climacteric, geratic period amnesia, mind agitation, prostate hyperplasia, property machine
The symptoms such as energy senilism have obvious righting regulation, nutritive body-building effect.
Another technical scheme of the present invention is for providing a kind of compound preparation for treating chronic pelvic pain
Preparation method, comprises the following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 145～232 parts, be subsequently adding PH
Regulator, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Rhizoma Smilacis Bockii volatile oil, adrenocortical hormone, estradiol valerate, dydrogesterone, Fructus Liquidambaris betulonic acid, breast
Ferritin, soybean lecithin, Xylaria sp. fungus ketone mix, and join in the mixed liquor prepared by step (1), so
It is placed on ultrasonic disperse 30～40min in ultrasonic disperse instrument, obtains described compound preparation.
Further, described compound preparation is made oral liquid by low temperature sterilization, fill.
Compared with prior art, beneficial effects of the present invention is embodied in: the compound preparation of the present invention has antiinflammatory and makees
With, immunosuppressive action, sedation-analgesia effect, and it has the effect of regulation patient's emotion, can be the most anti-
Only increase the weight of the state of an illness due to emotion reason, and ovarian function minimizing pelvic congestion can be regulated, alleviate pelvic pain；
Wherein medroxyprogestetone acetate can reduce pelvic congestion by suppression ovarian function, to alleviate pelvic pain, serotonin,
Powdered Wuling mycelia in combination, eleutheroside, oryzanol regulation patient's emotion, the pain increased owing to anxiety causes to prevent patient,
Stomach in Patients enterokinesia can be promoted simultaneously, promote that patient, to medicine and the absorption of nutritional labeling, promotes that patient recovers；
Rhizoma Smilacis Bockii volatile oil is mainly invigorated blood circulation, and promotes patient in conjunction with adrenocortical hormone, estradiol valerate, dydrogesterone
Resistance, particularly promote patient uterine and the ovary resistance to disease, Fructus Liquidambaris betulonic acid, breast ferrum
Albumen, Xylaria sp. fungus ketone act primarily as antibacterial and anti-inflammation functions, promote that patient recovers, and soybean lecithin combines lactoferrin
Nutrient substance needed for patient is provided, improves the immunity of patient, prevent from causing other pathological changes.Clinical verification is originally
The compound preparation of invention is evident in efficacy to treatment chronic pelvic pain, and side effect is little, has a extensive future.
Detailed description of the invention
Embodiment 1: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including with
The composition of lower weight portion: medroxyprogestetone acetate 17 parts, serotonin 15 parts, powdered Wuling mycelia in combination 13 parts, eleutheroside
10 parts, oryzanol 26 parts, lactoferrin 12 parts, preservative 0.8 part, emulsifying agent 6 parts, PH regulator
8 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 20 DEG C, concussion is cultivated
10 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: poloxamer.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；
Described PH regulator is: sodium dihydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from sending out
Changing affects drug effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 145 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Lactoferrin mixes, and joins in the mixed liquor prepared by step (1), is subsequently placed in ultrasonic disperse instrument super
Sound dispersion 30min, then makes oral liquid, every 10ml by low temperature sterilization, fill.
Embodiment 2: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including with
The composition of lower weight portion: medroxyprogestetone acetate 21.5 parts, serotonin 19 parts, powdered Wuling mycelia in combination 17 parts, Radix Et Caulis Acanthopanacis Senticosi
Glycoside 14.5 parts, oryzanol 30 parts, lactoferrin 18.5 parts, preservative 1 part, emulsifying agent 7.5 parts, PH
Regulator 11 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 25 DEG C, concussion is cultivated
11 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: poloxamer.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；
Described PH regulator is: sodium dihydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from sending out
Changing affects drug effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 188.5 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Lactoferrin mixes, and joins in the mixed liquor prepared by step (1), is subsequently placed in ultrasonic disperse instrument super
Sound dispersion 35min, then makes oral liquid, every 10ml by low temperature sterilization, fill.
Embodiment 3: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including with
The composition of lower weight portion: medroxyprogestetone acetate 26 parts, serotonin 23 parts, powdered Wuling mycelia in combination 21 parts, eleutheroside
19 parts, oryzanol 34 parts, lactoferrin 25 parts, preservative 1.2 parts, emulsifying agent 9 parts, PH regulator
14 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 30 DEG C, concussion is cultivated
12 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: poloxamer.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；
Described PH regulator is: sodium dihydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from sending out
Changing affects drug effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 232 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Lactoferrin mixes, and joins in the mixed liquor prepared by step (1), is subsequently placed in ultrasonic disperse instrument super
Sound dispersion 40min, then makes oral liquid, every 10ml by low temperature sterilization, fill.
Embodiment 4: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including with
The composition of lower weight portion: medroxyprogestetone acetate 17 parts, serotonin 15 parts, powdered Wuling mycelia in combination 13 parts, eleutheroside
10 parts, oryzanol 26 parts, lactoferrin 12 parts, preservative 0.8 part, emulsifying agent 6 parts, PH regulator
8 parts；Also include the composition of following weight portion: dydrogesterone 3 parts, Fructus Liquidambaris betulonic acid 9 parts, Xylaria sp. fungus
Ketone 7 parts, estradiol valerate 5 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 20 DEG C, concussion is cultivated
10 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: arabic gum.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；
Described PH regulator is: disodium hydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from sending out
Changing affects drug effect.
Wherein, described Xylaria sp. fungus ketone is extracted from big Xylaria sp. fungus by ultrasonic wave added with ethanol for solvent.
Xylaria sp. fungus ketone has adjustment effect, can improve immunologic function, strengthen hematopoietic function, to such as anemia, mistake
Dormancy, menoxenia, female climacteric, geratic period amnesia, mind agitation, prostate hyperplasia, sexual function
The symptoms such as senilism have obvious righting regulation, nutritive body-building effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 145 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Estradiol valerate, dydrogesterone, Fructus Liquidambaris betulonic acid, lactoferrin, Xylaria sp. fungus ketone mix, and join step
Suddenly, in the mixed liquor prepared by (1), it is subsequently placed in ultrasonic disperse 30min in ultrasonic disperse instrument, then passes through
Low temperature sterilization, fill make oral liquid, every 10ml.
Embodiment 5: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including with
The composition of lower weight portion: medroxyprogestetone acetate 21.5 parts, serotonin 19 parts, powdered Wuling mycelia in combination 17 parts, Radix Et Caulis Acanthopanacis Senticosi
Glycoside 14.5 parts, oryzanol 30 parts, lactoferrin 18.5 parts, preservative 1 part, emulsifying agent 7.5 parts, PH
Regulator 11 parts；Also include the composition of following weight portion: dydrogesterone 5.5 parts, Fructus Liquidambaris betulonic acid 11.5
Part, Xylaria sp. fungus ketone 11 parts, estradiol valerate 8 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 25 DEG C, concussion is cultivated
11 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: arabic gum.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；
Described PH regulator is: disodium hydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from sending out
Changing affects drug effect.
Wherein, described Xylaria sp. fungus ketone is extracted from big Xylaria sp. fungus by ultrasonic wave added with ethanol for solvent.
Xylaria sp. fungus ketone has adjustment effect, can improve immunologic function, strengthen hematopoietic function, to such as anemia, mistake
Dormancy, menoxenia, female climacteric, geratic period amnesia, mind agitation, prostate hyperplasia, sexual function
The symptoms such as senilism have obvious righting regulation, nutritive body-building effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 188.5 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Estradiol valerate, dydrogesterone, Fructus Liquidambaris betulonic acid, lactoferrin, Xylaria sp. fungus ketone mix, and join step
Suddenly, in the mixed liquor prepared by (1), it is subsequently placed in ultrasonic disperse 35min in ultrasonic disperse instrument, then passes through
Low temperature sterilization, fill make oral liquid, every 10ml.
Embodiment 6: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including with
The composition of lower weight portion: medroxyprogestetone acetate 26 parts, serotonin 23 parts, powdered Wuling mycelia in combination 21 parts, eleutheroside
19 parts, oryzanol 34 parts, lactoferrin 25 parts, preservative 1.2 parts, emulsifying agent 9 parts, PH regulator
14 parts；Also include the composition of following weight portion: dydrogesterone 8 parts, Fructus Liquidambaris betulonic acid 14 parts, charcoal angle
Bacterium ketone 15 parts, estradiol valerate 11 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 30 DEG C, concussion is cultivated
12 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: arabic gum.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；
Described PH regulator is: disodium hydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from sending out
Changing affects drug effect.
Wherein, described Xylaria sp. fungus ketone is extracted from big Xylaria sp. fungus by ultrasonic wave added with ethanol for solvent.
Xylaria sp. fungus ketone has adjustment effect, can improve immunologic function, strengthen hematopoietic function, to such as anemia, mistake
Dormancy, menoxenia, female climacteric, geratic period amnesia, mind agitation, prostate hyperplasia, sexual function
The symptoms such as senilism have obvious righting regulation, nutritive body-building effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 232 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Estradiol valerate, dydrogesterone, Fructus Liquidambaris betulonic acid, lactoferrin, Xylaria sp. fungus ketone mix, and join step
Suddenly, in the mixed liquor prepared by (1), it is subsequently placed in ultrasonic disperse 40min in ultrasonic disperse instrument, then passes through
Low temperature sterilization, fill make oral liquid, every 10ml.
Embodiment 7: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including with
The composition of lower weight portion: medroxyprogestetone acetate 17 parts, serotonin 15 parts, powdered Wuling mycelia in combination 13 parts, eleutheroside
10 parts, oryzanol 26 parts, lactoferrin 12 parts, preservative 0.8 part, emulsifying agent 6 parts, PH regulator
8 parts；Also include the composition of following weight portion: on Rhizoma Smilacis Bockii volatile oil 21 parts, soybean lecithin 9 parts, kidney
Gland 17-hydroxy-11-dehydrocorticosterone 8 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 20 DEG C, concussion is cultivated
10 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: tween.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；Described
PH regulator be: sodium dihydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from becoming
Change and affect drug effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 145 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Rhizoma Smilacis Bockii volatile oil, adrenocortical hormone, lactoferrin, soybean lecithin mix, and join step (1)
In prepared mixed liquor, be subsequently placed in ultrasonic disperse 30min in ultrasonic disperse instrument, then by low temperature sterilization,
Oral liquid, every 10ml are made in fill.
Embodiment 8: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including with
The composition of lower weight portion: medroxyprogestetone acetate 21.5 parts, serotonin 19 parts, powdered Wuling mycelia in combination 17 parts, Radix Et Caulis Acanthopanacis Senticosi
Glycoside 14.5 parts, oryzanol 30 parts, lactoferrin 18.5 parts, preservative 1 part, emulsifying agent 7.5 parts, PH
Regulator 11 parts；Also include the composition of following weight portion: Rhizoma Smilacis Bockii volatile oil 25 parts, soybean lecithin 12.5
Part, adrenocortical hormone 10.5 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 25 DEG C, concussion is cultivated
11 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: tween.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；Described
PH regulator be: sodium dihydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from becoming
Change and affect drug effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 188.5 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Rhizoma Smilacis Bockii volatile oil, adrenocortical hormone, lactoferrin, soybean lecithin mix, and join step (1)
In prepared mixed liquor, be subsequently placed in ultrasonic disperse 35min in ultrasonic disperse instrument, then by low temperature sterilization,
Oral liquid, every 10ml are made in fill.
Embodiment 9: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including with
The composition of lower weight portion: medroxyprogestetone acetate 26 parts, serotonin 23 parts, powdered Wuling mycelia in combination 21 parts, eleutheroside
19 parts, oryzanol 34 parts, lactoferrin 25 parts, preservative 1.2 parts, emulsifying agent 9 parts, PH regulator
14 parts；Also include the composition of following weight portion: Rhizoma Smilacis Bockii volatile oil 29 parts, soybean lecithin 16 parts, kidney
Upper gland 17-hydroxy-11-dehydrocorticosterone 13 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 30 DEG C, concussion is cultivated
12 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: tween.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；Described
PH regulator be: sodium dihydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from becoming
Change and affect drug effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 232 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Rhizoma Smilacis Bockii volatile oil, adrenocortical hormone, lactoferrin, soybean lecithin mix, and join step (1)
In prepared mixed liquor, be subsequently placed in ultrasonic disperse 40min in ultrasonic disperse instrument, then by low temperature sterilization,
Oral liquid, every 10ml are made in fill.
Embodiment 10: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including
The composition of following weight portion: medroxyprogestetone acetate 17 parts, serotonin 15 parts, powdered Wuling mycelia in combination 13 parts, Radix Et Caulis Acanthopanacis Senticosi
Glycoside 10 parts, oryzanol 26 parts, lactoferrin 12 parts, preservative 0.8 part, emulsifying agent 6 parts, PH regulate
Agent 8 parts；Also include the composition of following weight portion: dydrogesterone 3 parts, Fructus Liquidambaris betulonic acid 9 parts, charcoal angle
Bacterium ketone 7 parts, estradiol valerate 5 parts, Rhizoma Smilacis Bockii volatile oil 21 parts, soybean lecithin 9 parts, adrenal gland's skin
Matter hormone 8 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 20 DEG C, concussion is cultivated
10 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: tween.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；Described
PH regulator be: sodium dihydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from becoming
Change and affect drug effect.
Wherein, described Xylaria sp. fungus ketone is extracted from big Xylaria sp. fungus by ultrasonic wave added with ethanol for solvent.
Xylaria sp. fungus ketone has adjustment effect, can improve immunologic function, strengthen hematopoietic function, to such as anemia, mistake
Dormancy, menoxenia, female climacteric, geratic period amnesia, mind agitation, prostate hyperplasia, sexual function
The symptoms such as senilism have obvious righting regulation, nutritive body-building effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 145 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Rhizoma Smilacis Bockii volatile oil, adrenocortical hormone, estradiol valerate, dydrogesterone, Fructus Liquidambaris betulonic acid, breast
Ferritin, soybean lecithin, Xylaria sp. fungus ketone mix, and join in the mixed liquor prepared by step (1), so
It is placed on ultrasonic disperse 30min in ultrasonic disperse instrument, then makes oral liquid by low temperature sterilization, fill, often
Prop up 10ml.
Embodiment 11: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including
The composition of following weight portion: medroxyprogestetone acetate 21.5 parts, serotonin 19 parts, powdered Wuling mycelia in combination 17 parts, thorn five
Add glycoside 14.5 parts, oryzanol 30 parts, lactoferrin 18.5 parts, preservative 1 part, emulsifying agent 7.5 parts, PH
Regulator 11 parts；Also include the composition of following weight portion: dydrogesterone 5.5 parts, Fructus Liquidambaris betulonic acid 11.5
Part, Xylaria sp. fungus ketone 11 parts, estradiol valerate 8 parts, Rhizoma Smilacis Bockii volatile oil 25 parts, soybean lecithin 12.5
Part, adrenocortical hormone 10.5 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 25 DEG C, concussion is cultivated
11 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: tween.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；Described
PH regulator be: sodium dihydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from becoming
Change and affect drug effect.
Wherein, described Xylaria sp. fungus ketone is extracted from big Xylaria sp. fungus by ultrasonic wave added with ethanol for solvent.
Xylaria sp. fungus ketone has adjustment effect, can improve immunologic function, strengthen hematopoietic function, to such as anemia, mistake
Dormancy, menoxenia, female climacteric, geratic period amnesia, mind agitation, prostate hyperplasia, sexual function
The symptoms such as senilism have obvious righting regulation, nutritive body-building effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 188.5 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Rhizoma Smilacis Bockii volatile oil, adrenocortical hormone, estradiol valerate, dydrogesterone, Fructus Liquidambaris betulonic acid, breast
Ferritin, soybean lecithin, Xylaria sp. fungus ketone mix, and join in the mixed liquor prepared by step (1), so
It is placed on ultrasonic disperse 35min in ultrasonic disperse instrument, then makes oral liquid by low temperature sterilization, fill, often
Prop up 10ml.
Embodiment 12: the present embodiment prepares a kind of compound oral liquid for treating chronic pelvic pain, including
The composition of following weight portion: medroxyprogestetone acetate 26 parts, serotonin 23 parts, powdered Wuling mycelia in combination 21 parts, Radix Et Caulis Acanthopanacis Senticosi
Glycoside 19 parts, oryzanol 34 parts, lactoferrin 25 parts, preservative 1.2 parts, emulsifying agent 9 parts, PH regulate
Agent 14 parts；Also include the composition of following weight portion: dydrogesterone 8 parts, Fructus Liquidambaris betulonic acid 14 parts, charcoal
On angle bacterium ketone 15 parts, estradiol valerate 11 parts, Rhizoma Smilacis Bockii volatile oil 29 parts, soybean lecithin 16 parts, kidney
Gland 17-hydroxy-11-dehydrocorticosterone 13 parts.
Wherein, described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology,
And it is processed into powdered Wuling mycelia in combination.Detailed process is: WULINGJUN be inoculated into containing water, carbonizable substance, nitrogen thing
On the fluid medium of matter, mineral element and auxin substance composition, sealing, at 30 DEG C, concussion is cultivated
12 days, media surface there will be one layer of mycelium, is then separated by the mycelium on culture medium top layer, is dried.
Smash and i.e. obtain described powdered Wuling mycelia in combination.
Wherein, described preservative is: methyl hydroxybenzoate.For organic intermediate, it is used for medicine, food, perfume (or spice)
Material, the anticorrosive additive of film, be strong fungicide, and toxicity is extremely low, non-stimulated to human body.By para hydroxybenzene
Formic acid and methanol are esterified refined under sulfuric acid catalysis and obtain.Can effectively prevent medicine from going bad and lose drug effect；Described
Emulsifying agent is: tween.Emulsifying agent mainly promotes the dispersion of mutual exclusive system, forms homogeneous system；Described
PH regulator be: sodium dihydrogen phosphate.PH regulator mainly regulates the PH of solution, prevents PH from becoming
Change and affect drug effect.
Wherein, described Xylaria sp. fungus ketone is extracted from big Xylaria sp. fungus by ultrasonic wave added with ethanol for solvent.
Xylaria sp. fungus ketone has adjustment effect, can improve immunologic function, strengthen hematopoietic function, to such as anemia, mistake
Dormancy, menoxenia, female climacteric, geratic period amnesia, mind agitation, prostate hyperplasia, sexual function
The symptoms such as senilism have obvious righting regulation, nutritive body-building effect.
The preparation method of a kind of compound oral liquid for treating chronic pelvic pain prepared by the present embodiment, including
Following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 232 parts, be subsequently adding PH regulation
Agent, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol,
Rhizoma Smilacis Bockii volatile oil, adrenocortical hormone, estradiol valerate, dydrogesterone, Fructus Liquidambaris betulonic acid, breast
Ferritin, soybean lecithin, Xylaria sp. fungus ketone mix, and join in the mixed liquor prepared by step (1), so
It is placed on ultrasonic disperse 40min in ultrasonic disperse instrument, then makes oral liquid by low temperature sterilization, fill, often
Prop up 10ml.
Experimental verification
One. animal toxicity test:
1. experimental animal selects: randomly choosing 200 female rats, then the abdominal cavity of mechanical damage rat, makes
There are the various symptoms of abdominal cavity pain in rat, then rat is randomly divided into 5 groups, and often group 40, remembers respectively
For A group, B group, C group, D group, E group；Each group rat symptom, without significant difference, has comparability.
2. animal test method: A group, B group, C group, D group take respectively the embodiment of the present invention 2,5,8,
The compound oral liquid of 11 preparations, each one, three times a day；E group takes the embodiment of the present invention 11 preparation
Compound oral liquid, each 6, three times a day；Each group rat continuous use 15 days.
3. result of the test: after medication terminates, each group rat is all without death, wherein A group, B group, C group, D
The group various symptom of rat all disappears, and recovers good, and clinical examination abdominal cavity is without infecting；E group rat is dissected,
Histoorgan is taken medicine the damage caused due to excess without any.Therefore the compound preparation safety non-toxic of the present invention, and
Evident in efficacy.
Two. clinical treatment:
1. case selection: inventor randomly chooses the trouble suffering from chronic pelvic pain that certain hospital section accepts for medical treatment the period
Person 150 people, the course of disease 3～20 months, each group patient, without significant difference, has comparability；Then by patient with
Machine is divided into 5 groups, and wherein four groups is experimental group, and one group is matched group；Often organize 30 people.
2. Therapeutic Method: experimental group takes the compound oral liquid of the embodiment of the present invention 2,5,8,11 preparation respectively,
Each one；Matched group Aspirin, dose taken by package insert regulation, each group patient every day three
Secondary take medicine, take medicine continuously 10 days.
3, observation index
Use VAS scale to judge the pain degree (0～10.0 as painless, and 10 is the most bitterly) of muscle, observe simultaneously
Patient muscle's pain, dysfunction and sleep state, carry out efficacy evaluation after 3 courses for the treatment of.
4. criterion of therapeutical effect:
Curing: pain disappears, clinical examination abdominal cavity recovers good；
Effective: accidental pain, clinical examination recovers good；
Invalid: symptom is not improved.
5. therapeutic outcome: before and after each group patient treatment outcome and treatment, pain VAS is measured and is compared as follows table:
| Group | Healing/example | Effectively/example | Invalid/example | Effective percentage/% | VAS (front) | VAS (afterwards) |
| Embodiment 2 | 25 | 2 | 3 | 90 | 10 | 5 |
| Embodiment 5 | 25 | 3 | 2 | 93.3 | 10 | 5 |
| Embodiment 8 | 26 | 2 | 2 | 93.3 | 10 | 4 |
| Embodiment 11 | 27 | 2 | 1 | 96.7 | 10 | 2 |
| Matched group | 23 | 3 | 4 | 86.7 | 10 | 9 |
6. conclusion: from above-mentioned clinical treatment case, the compound preparation of the present invention has good clinical treatment
Effect, its effective percentage reaches more than 90%, is possible not only to the pain of reduction of patient, and can regulate the feelings of patient
Thread, also can improve patient's immunity, and safe secondary effect is little, has a extensive future.
Although the present invention being described and illustrated with reference to its specific embodiments, but those skilled in the art will appreciate that
Arrive, without departing from the spirit and scope of the present invention it can be variously modified, revise and replace.
Such as, due to the change of responding ability of the people of treated particular condition, beyond preferred dose as explained above
Effective dose may be suitable for.Similarly, it was observed that pharmacology respond may basis and rely on selected given activity
Compound or whether there is pharmaceutical carrier and preparation type and mode of administration used and become, according to the mesh of the present invention
And practice be contemplated in result this kind of expection change or difference.Therefore, the invention is intended to only by following patent
The scope required limits and these claim should be explained in rational degree as broadly as possible.
Claims (8)
1. the compound preparation being used for treating chronic pelvic pain, it is characterized in that, described compound preparation includes the composition of following weight portion: medroxyprogestetone acetate 17～26 parts, serotonin 15～23 parts, powdered Wuling mycelia in combination 13～21 parts, eleutheroside 10～19 parts, oryzanol 26～34 parts, lactoferrin 12～25 parts, preservative 0.8～1.2 parts, emulsifying agent 6～9 parts, PH regulator 8～14 parts.
A kind of compound preparation for treating chronic pelvic pain, it is characterized in that, also include the composition of following weight portion: dydrogesterone 3～8 parts, Fructus Liquidambaris betulonic acid 9～14 parts, Xylaria sp. fungus ketone 7～15 parts, estradiol valerate 5～11 parts.
A kind of compound preparation for treating chronic pelvic pain, it is characterised in that also include the composition of following weight portion: Rhizoma Smilacis Bockii volatile oil 21～29 parts, soybean lecithin 9～16 parts, adrenocortical hormone 8～13 parts.
A kind of compound preparation for treating chronic pelvic pain, it is characterised in that described powdered Wuling mycelia in combination is finally successfully to have cultivated WULINGJUN filament by submerged fermentation technology, and be processed into powdered Wuling mycelia in combination.
A kind of compound preparation for treating chronic pelvic pain, it is characterised in that described preservative is: methyl hydroxybenzoate；Described emulsifying agent is: any one in lecithin, poloxamer, arabic gum, tween and span；Described PH regulator is: the one in sodium dihydrogen phosphate, disodium hydrogen phosphate.
A kind of compound preparation for treating chronic pelvic pain, it is characterised in that described Xylaria sp. fungus ketone is extracted from big Xylaria sp. fungus by ultrasonic wave added with ethanol for solvent.
The preparation method of a kind of compound preparation for treating chronic pelvic pain, it is characterised in that comprise the following steps:
(1) in the emulsifying agent of described weight portion, add the water for injection of 145～232 parts, be subsequently adding PH regulator, preservative, mix homogeneously, obtain mixed liquor；
(2) by the medroxyprogestetone acetate of described weight portion, serotonin, powdered Wuling mycelia in combination, eleutheroside, oryzanol, Rhizoma Smilacis Bockii volatile oil, adrenocortical hormone, estradiol valerate, dydrogesterone, Fructus Liquidambaris betulonic acid, lactoferrin, soybean lecithin, the mixing of Xylaria sp. fungus ketone, join in the mixed liquor prepared by step (1), it is subsequently placed in ultrasonic disperse 30～40min in ultrasonic disperse instrument, obtains described compound preparation.
The preparation method of a kind of compound preparation for treating chronic pelvic pain, it is characterised in that described compound preparation is made oral liquid by low temperature sterilization, fill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610273805.2A CN105963687A (en) | 2016-04-27 | 2016-04-27 | Compound preparation for treating chronic pelvic pain and preparation method of compound preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610273805.2A CN105963687A (en) | 2016-04-27 | 2016-04-27 | Compound preparation for treating chronic pelvic pain and preparation method of compound preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105963687A true CN105963687A (en) | 2016-09-28 |
Family
ID=56994091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610273805.2A Pending CN105963687A (en) | 2016-04-27 | 2016-04-27 | Compound preparation for treating chronic pelvic pain and preparation method of compound preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105963687A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101468133A (en) * | 2007-12-26 | 2009-07-01 | 北京卓越同创药物研究院 | Pharmaceutical composition for treating inflammation of gynecology |
| CN101732539A (en) * | 2008-11-04 | 2010-06-16 | 朱志宏 | Medicament for treating gynecological diseases and preparation method thereof |
| CN102089320A (en) * | 2008-01-24 | 2011-06-08 | 埃斯佩兰斯医药公司 | Lytic domain fusion constructs and methods of making and using same |
| CN102362948A (en) * | 2011-04-26 | 2012-02-29 | 湖北福人药业股份有限公司 | Chinese medicinal composition for treating chronic pelvic inflammatory disease |
| CN102415995A (en) * | 2011-12-09 | 2012-04-18 | 广东众生药业股份有限公司 | Progesterone supersaturated self-microemulsion composition and preparation method thereof |
| CN103145779A (en) * | 2011-12-07 | 2013-06-12 | 上海来益生物药物研究开发中心有限责任公司 | 3,5-dimethyl-8-(3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-oxo) heterochromatic original alkyl-1-one, preparation method and application thereof |
| CN103800299A (en) * | 2014-02-25 | 2014-05-21 | 刘艳青 | Medroxyprogesterone tablet and preparation process thereof |
| CN104997789A (en) * | 2006-10-24 | 2015-10-28 | 利普生物药剂公司 | Compositions and methods for suppressing endometrial proliferation |
| CN105130957A (en) * | 2009-05-29 | 2015-12-09 | 拉夸里亚创药株式会社 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
| CN105380932A (en) * | 2015-10-22 | 2016-03-09 | 苏州普罗达生物科技有限公司 | Application of xylaria ketone in preparing medicine for resisting colpitis mycotica |
-
2016
- 2016-04-27 CN CN201610273805.2A patent/CN105963687A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997789A (en) * | 2006-10-24 | 2015-10-28 | 利普生物药剂公司 | Compositions and methods for suppressing endometrial proliferation |
| CN101468133A (en) * | 2007-12-26 | 2009-07-01 | 北京卓越同创药物研究院 | Pharmaceutical composition for treating inflammation of gynecology |
| CN102089320A (en) * | 2008-01-24 | 2011-06-08 | 埃斯佩兰斯医药公司 | Lytic domain fusion constructs and methods of making and using same |
| CN101732539A (en) * | 2008-11-04 | 2010-06-16 | 朱志宏 | Medicament for treating gynecological diseases and preparation method thereof |
| CN105130957A (en) * | 2009-05-29 | 2015-12-09 | 拉夸里亚创药株式会社 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
| CN102362948A (en) * | 2011-04-26 | 2012-02-29 | 湖北福人药业股份有限公司 | Chinese medicinal composition for treating chronic pelvic inflammatory disease |
| CN103145779A (en) * | 2011-12-07 | 2013-06-12 | 上海来益生物药物研究开发中心有限责任公司 | 3,5-dimethyl-8-(3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-oxo) heterochromatic original alkyl-1-one, preparation method and application thereof |
| CN102415995A (en) * | 2011-12-09 | 2012-04-18 | 广东众生药业股份有限公司 | Progesterone supersaturated self-microemulsion composition and preparation method thereof |
| CN103800299A (en) * | 2014-02-25 | 2014-05-21 | 刘艳青 | Medroxyprogesterone tablet and preparation process thereof |
| CN105380932A (en) * | 2015-10-22 | 2016-03-09 | 苏州普罗达生物科技有限公司 | Application of xylaria ketone in preparing medicine for resisting colpitis mycotica |
Non-Patent Citations (3)
| Title |
|---|
| 杨远新: "慢性盆腔疼痛65例疗效观察", 《浙江预防医学》 * |
| 王林编: "《西京妇产科临床工作手册》", 31 August 2011, 第四军医大学出版社 * |
| 邢运贞等主编: "《妇产科基层医师处方手册》", 30 June 2014, 河北科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103751310B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating fascitis | |
| CN106309474A (en) | Application of ozonized oil in hyperplasia diseases and infertility | |
| CN102580000B (en) | Medicament for curing cancer pain and preparation method thereof | |
| CN102225181B (en) | Medicament for treating benign prostatic hyperplasia disease and preparation method thereof | |
| CN101721528A (en) | Medicine composition for treating chronic prostatitis | |
| CN104208242B (en) | One treats prostatitic external use plaster and preparation method thereof | |
| CN103933294A (en) | Plant extracting composition for sexual dysfunction | |
| CN106581246A (en) | Traditional Chinese medicine paste for treating hemorrhoids and preparation method thereof | |
| CN105963687A (en) | Compound preparation for treating chronic pelvic pain and preparation method of compound preparation | |
| CN102670687B (en) | Health care product composition or drug composition for preventing or treating prostatic diseases | |
| CN105267472A (en) | Traditional Chinese medicine medicament for treating gynecological diseases and applications thereof | |
| CN101678062A (en) | Drugs for treating and preventing benign prostatic hyperplasia, prostatitis, impotency, infertility and prostate cancer and a method for the use thereof | |
| CN103784521B (en) | A kind ofly coordinate Chinese medicine composition of operative treatment peritoneal abscess and preparation method thereof | |
| CN101940652B (en) | Chinese medicinal liniment for treating psoriasis, multiple kinds of stubborn dermatitis and pruritus | |
| CN101816762A (en) | Medicinal preparation for treating colpitis and preparation method thereof | |
| CN1488394A (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN104784627A (en) | Traditional Chinese medicine externally used film agent used for treatment surgical open or closed injury and preparation method thereof | |
| CN103893447B (en) | One kind treats prostatitic medicine and preparation method thereof | |
| CN115414456B (en) | Traditional Chinese medicine composition for treating hemorrhoids and application thereof | |
| CN104587209B (en) | A kind of medicament for the treatment of sciatica | |
| CN114344372B (en) | Traditional Chinese medicine composition for treating primary liver cancer and preparation method thereof | |
| CN104800811B (en) | A kind of composition for treating or preventing hyperplasia of prostate and its application | |
| CN104547434B (en) | One treats chronic prostatitis Chinese medicine composition | |
| CN100408085C (en) | Snow lotus preparation for treating prostate disease | |
| CN105853832A (en) | Traditional Chinese medicine composition for treating chronic prostatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160928 |
|
| RJ01 | Rejection of invention patent application after publication |